Metastases of Predominantly Dopamine-secreting Phaeochromocytoma that did not Accumulate Meta-iodobenzylguanidine: Imaging with Whole Body Positron Emission Tomography using 18 F-labelled Deoxyglucose

Taniguchi, Ken; Ishizu, Koji; Torizuka, Tatsuo; Hasegawa, Shuichi; Okawada, Taketoshi; Ozawa, Tomohiro; Iino, Kazumi; Taniguchi, Miwa; Ikematsu, Yoshito; Nishiwaki, Yoshiro; Kida, Hideo; Waki, Shinji; Uchimura, Masayuki

doi:10.1080/11024150152717733

Cited by 19 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nifedipine, on the other hand, can cause prolonged retention of the tracer in PCCs/PGLs [14]. Very high serum catecholamines levels may be associated with lower MIBG accumulation [15–18]. To date, many of these interactions are suspected on the basis of in vitro/preclinical observations or only expected on the basis of their pharmacological properties, and thus should be interpreted with caution.…”

Section: I-iobenguane/123i-metaiodobenzylguanidine Scintigraphymentioning

confidence: 99%

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

Taïeb

Timmers

Hindié

et al. 2012

Eur J Nucl Med Mol Imaging

222

143

View full text Add to dashboard Cite

Purpose Radionuclide imaging of phaeochromocytomas (PCCs) and paragangliomas (PGLs) involves various functional imaging techniques and approaches for accurate diagnosis, staging and tumour characterization. The purpose of the present guidelines is to assist nuclear medicine practitioners in performing, interpreting and reporting the results of the currently available SPECT and PET imaging approaches. These guidelines are intended to present information specifically adapted to European practice. Methods Guidelines from related fields, issued by the European Association of Nuclear Medicine and the Society of Nuclear Medicine, were taken into consideration and are partially integrated within this text. The same was applied to the relevant literature, and the final result was discussed with leading experts involved in the management of patients with PCC/PGL. The information provided should be viewed in the context of local conditions, laws and regulations. Conclusion Although several radionuclide imaging modalities are considered herein, considerable focus is given to PET imaging which offers high sensitivity targeted molecular imaging approaches.

show abstract

Section: I-iobenguane/123i-metaiodobenzylguanidine Scintigraphymentioning

confidence: 99%

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

Taïeb

Timmers

Hindié

et al. 2012

Eur J Nucl Med Mol Imaging

222

143

View full text Add to dashboard Cite

show abstract

“…The third dopamine‐secreting tumor was not scanned [2]. Pheochromocytomas that predominantly secrete dopamine while secreting lower levels of epinephrine or norepinephrine are also less likely to enhance with MIBG scans than tumors that do not secrete any dopamine [9]. MIBG is a radioiodinated norepinephrine analog that follows the same kinetic pathways as the hormone [10].…”

Section: Diagnosismentioning

confidence: 99%

“…All four of these tumors, however, did enhance with FDG‐PET [12]. Another study reported using FDG‐PET scans to detect metastases in a predominantly dopamine‐secreting tumor that did not enhance with MIBG [9]. [ 111 In]Octreotide scans (radiolabeled somatostatin analog) are better at detecting malignant pheochromocytomas than benign ones.…”

Section: Diagnosismentioning

confidence: 99%

“…Some authors have suggested using whole-body positron emission tomography with 18 F-labeled deoxyglucose (FDG-PET) in the detection of pheochromocytomas [9,12]. One study that reported imaging results in mixed (norepinephrine/epinephrine and dopamine) cathecholamine-secreting tumors found four tumors that secreted dopamine did not enhance with MIBG.…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Dopamine‐secreting Pheochromocytomas: In Search of a Syndrome

Dubois

Gray

2005

World j. surg.

View full text Add to dashboard Cite

Pheochromocytomas rarely produce dopamine as the only catecholamine. Two cases are reported here, and a review of the literature was conducted. Unlike norepinephrine-and epinephrine-secreting tumors, dopamine-secreting pheochromocytomas lack a classic clinical presentation and are often asymptomatic. Urinary and serum metabolites cannot be relied on to make the diagnosis, and serum or urine dopamine levels (or both) must be measured when dealing with a potential pheochromocytoma. Dopamine-secreting tumors are less likely to enhance with metaiodobenzylguanidine (MIBG) scanning and may benefit from the use of positron emission tomography. Treatment is en bloc surgical excision; but unlike other pheochromocytomas, alpha-blockade is not indicated as it may lead to hypotension and cardiovascular collapse. Metyrosine is a medication that can be useful for preoperative control of symptoms from these tumors. The function of metyrosine is to block dopamine synthesis; it has no alpha-blocking effect. This medication is an option for controlling symptoms but should not be used routinely in these patients. The prognosis for patients with these tumors is worse than for those with an epinephrine- and norepinephrine-secreting tumor. Because of their asymptomatic nature, dopamine-secreting pheochromocytomas tend to be detected later and are more likely to be malignant at the time of diagnosis.

show abstract

Tumors of the Endocrine System

Norton

Oncology

View full text Add to dashboard Cite

Metastases of Predominantly Dopamine-secreting Phaeochromocytoma that did not Accumulate Meta-iodobenzylguanidine: Imaging with Whole Body Positron Emission Tomography using 18 F-labelled Deoxyglucose

Cited by 19 publications

References 7 publications

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

Dopamine‐secreting Pheochromocytomas: In Search of a Syndrome

Tumors of the Endocrine System

Contact Info

Product

Resources

About